Your session is about to expire
← Back to Search
Unknown
Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension
Phase 1 & 2
Waitlist Available
Led By David Wirta, MD
Research Sponsored by JeniVision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to day 28 of treatment
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called JV-GL1 to see if it can safely lower eye pressure in adults with open-angle glaucoma or ocular hypertension. By reducing eye pressure, JV-GL1 might help protect vision.
Eligible Conditions
- Ocular Hypertension
- Open-Angle Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to day 28 of treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to day 28 of treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Intraocular Pressure (IOP)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Randomized Part 2, Arm 2Experimental Treatment1 Intervention
Dose 2 selected in Part I
Group II: Randomized Part 2, Arm 1Experimental Treatment1 Intervention
Dose 1 selected in Part I
Group III: Randomized Part 2, Arm 3Active Control1 Intervention
Find a Location
Who is running the clinical trial?
JeniVision, Inc.Lead Sponsor
David Wirta, MDPrincipal InvestigatorEye Research Foundation, Inc.
3 Previous Clinical Trials
718 Total Patients Enrolled
1 Trials studying Ocular Hypertension
77 Patients Enrolled for Ocular Hypertension